Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 24, 2009 Selena Maranjian	Focus Fuels a Comeback Recently, a bunch of mutual funds have been enjoying strong comebacks after the devastation of 2008.
The Motley Fool January 11, 2005 Selena Maranjian	A Sturdy Fund Reopens Here's your chance to have a great investor invest for you. Oakmark Select fund is now open to new investors.
The Motley Fool June 27, 2007 Selena Maranjian	Meet Some Weird Mutual Funds Here is a look at some odd mutual funds.
The Motley Fool June 26, 2009 Dan Caplinger	The Danger Lurking in Your Portfolio Think you're diversified? Think again.
The Motley Fool April 13, 2007 Selena Maranjian	Putting It All on One Stock If you think mutual funds might be for you, don't assume that means you have to give up on the idea of concentrating your portfolio on your best ideas.
The Motley Fool November 3, 2009 Selena Maranjian	How Much Is Management Costing You? Be picky. Look at fees. Look at a fund's turnover, because the higher the turnover, the higher the taxes on gains will likely be. Look at the long-term returns, too, because given the thousands of mutual funds out there, many are run by not-very-good managers.
The Motley Fool June 4, 2009 Dan Caplinger	These Buyers Will Launch Stocks Higher For fund managers who've kept money on the sidelines this year, the pressure's on to get fully invested -- and when those holdouts start buying, they'll likely push stocks even higher.
The Motley Fool July 17, 2008 Brian Orelli	Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release
The Motley Fool October 20, 2011 Brian Orelli	Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other.
The Motley Fool October 26, 2005 Selena Maranjian	Does Your Fund Make You Cringe? The bottom line here is that the more you learn about any funds you own or are thinking about buying into, the better off you'll likely be. Make sure your funds are a good fit for your investing style and temperament.
The Motley Fool December 3, 2008 Dan Caplinger	The Year-End Mistake You Don't Want to Make If you prefer to use mutual funds rather than individual stocks to invest, there's one expensive tax mistake that you'll want to be sure to avoid.
The Motley Fool August 31, 2005 Selena Maranjian	What's in Your Fund? Are you a redundant investor?
The Motley Fool November 16, 2009 Selena Maranjian	Exciting Young Funds Buck the Trend Death and rebirth in the land of mutual funds.
The Motley Fool March 9, 2009 Dan Caplinger	You're Not as Diversified as You Think While the right mix of mutual funds can help you create a diversified portfolio that gives you broad exposure to a wide range of financial markets, you have to stay on the lookout to avoid unnecessary overlap in the stocks your funds own.
The Motley Fool July 16, 2008 Brian Orelli	J&J's Lesson to Investors: Diversify! Johnson & Johnson's second-quarter earnings report gives investors an object lesson of the benefits of the principle of diversification.
The Motley Fool February 6, 2006 Selena Maranjian	Fund Winners and Losers Which funds did the best and worst in 2005? Ultra Japan ProFund... ING Russia... Fidelity Select Paper & Forest Products... Van Wagoner Emerging Growth... etc.
The Motley Fool January 13, 2009 Selena Maranjian	Is Your Mutual Fund One of the Worst? The dismal performance of some top mutual funds in 2008 is probably enough to send most investors out the door, and to keep many would-be investors away. But should these funds really be avoided? Perhaps not.
The Motley Fool September 17, 2010 James Early	Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care.
The Motley Fool February 24, 2009 Brian Orelli	Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success.
The Motley Fool February 17, 2010 Selena Maranjian	Investments for the Indecisive Can't make up your mind? ETFs might help.
The Motley Fool October 14, 2008 Brian Orelli	Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace.
The Motley Fool January 16, 2007 Selena Maranjian	When Big Funds Are Bad You can take much of the headache out of investing and meet the market average by investing in index funds.
The Motley Fool June 30, 2009 Brian Orelli	Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward.
The Motley Fool October 7, 2010 Anand Chokkavelu	How Johnson & Johnson Really Makes Money Hint: It's not Tylenol.
The Motley Fool August 17, 2007 Selena Maranjian	Beware of Seemingly Similar ETFs While ETFs can quickly get you invested in a certain index or a certain sector, beware, because similar-sounding ones are not necessarily so similar, and they won't serve you equally well.
The Motley Fool January 25, 2005 Selena Maranjian	Lumpy Results Ahead Don't expect smooth sailing when you're investing. In the short run, the stock market is especially volatile, and your performance over a few months could be a gain of 25%, or a loss of 18%, or something else.
The Motley Fool August 19, 2009 Selena Maranjian	Lessons I've Learned -- the Hard Way Ignore a few of these lessons, and your retirement might end up a few more years away than you thought it would be.
The Motley Fool April 13, 2004 Alyce Lomax	J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter.
The Motley Fool February 25, 2011 Rex Moore	Rising Star Buys: 2 Health Care Winners Abbott Laboratories and Johnson & Johnson are being added to the Motley Fool multivitamin portfolio.
The Motley Fool August 24, 2009 Brian Orelli	J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell.
The Motley Fool January 20, 2009 Brian Orelli	Johnson & Johnson Nimble ... for Now The health-care giant reports increasing earnings, despite falling revenue.
Investment Advisor July 2009 James J. Green	Changing Shades of Blue Among the Massachusetts Investors Trust holdings 85 years ago were Nash Motors Co., the New York Central Railroad, Naumkeag Steam Cotton Co., and the Punta Alegre Sugar Co.
The Motley Fool November 15, 2011 Shubh Datta	AIG and Losses Go Hand in Hand AIG posts biggest quarterly loss since 2009.
The Motley Fool February 24, 2011 Brian Orelli	Abbott: 1, Johnson & Johnson: 0 -- For Now Abbott Labs got a ruling overturned yesterday that would have cost the company $1.8 billion, yet investors let shares slip down 1%.
The Motley Fool October 18, 2010 Selena Maranjian	Beware of Misleading Mutual Funds Getting swayed by an inaccurate fund name could cost you dearly.
The Motley Fool September 23, 2010 Brian Orelli	This Recall Should Bug You Abbott Labs announces a recall of some types of its Similac baby formula because it found beetles and their larvae in an area of one of its plants.
The Motley Fool March 24, 2011 Anand Chokkavelu	Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund."
The Motley Fool February 19, 2009 Dan Caplinger	The Only Way to Stop Losing Money By taking charge of investing your own large portfolio, you can save a bundle in fees.
The Motley Fool August 9, 2007 Ryan Fuhrmann	Diversification Pays at AIG This morning, AIG updated investors on its sub-prime exposure. Thanks to their product and global geographic diversification, the insurance and financial services giant can likely ride out any further turmoil.
The Motley Fool June 4, 2010 Jim Mueller	The Changing Face of Abbott Abbott Labs' shift in revenue sources has been a boon over the last five years.
AskMen.com April 14, 2002 Rashmikant Patel	Starting A Portfolio Investors can easily understand and build a portfolio that conforms to their needs...
The Motley Fool January 12, 2009 Brian Orelli	Abbott Eyes New Growth Abbott announces it's buying eye-care specialist Advanced Medical Optics for $22 per share -- nearly 150% higher than Friday's close on the stock.
The Motley Fool March 16, 2009 Dan Caplinger	This Wealth-Killing Blunder Will Cost You Some commentators are arguing that the way millions of investors put money to work in the markets through mutual funds has fundamental flaws that simply can't be overcome.
The Motley Fool February 28, 2005	Understanding "Window Dressing" Some mutual funds are pulling the wool over your eyes.
Insurance & Technology August 7, 2009 Anthony O'Donnell	AIG Board Names Harvey Golub Non-Executive Chairman Golub will assume his new role on Aug. 10, the same day Robert Benmosche officially takes on the president and CEO job for AIG.
The Motley Fool May 13, 2011 Rich Smith	AIG IPO A-OK? It looks to Wall Street like the AIG IPO is going to happen after all.
The Motley Fool March 17, 2009 Brian Orelli	Stent Wars, Episode III: The Rise of Xience V Johnson & Johnson lose the lead in the stent war race, but this is a marathon, not a footrace.
The Motley Fool November 15, 2005 Stephen D. Simpson	Guidant, J&J Kiss and Make Up The two companies hammered out a revised merger agreement that continues J&J's buyout of Guidant, but at a lower price. So what does this mean for the med-tech space, assuming that this deal actually goes through? Investors, take note.
The Motley Fool April 24, 2008 Zoe Van Schyndel	Taking Profits out of the Ground Natural resources funds have performed well lately, but they aren't all the same.
The Motley Fool November 26, 2007 Brian Orelli	Johnson & Johnson Reorganizes -- Who Wins? Johnson & Johnson announces the second phase of its reorganization plan. While it may take years to see whether the measures will help J&J, some other companies could benefit far more quickly.